Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Corneal lesion, Oral disorder, Urticaria
Clinical narrative: 2 weeks after 2nd booster patient had chronic hives, patient had Urticaria/patient had a more aggressive bout of hives/had a major reaction with hives all over trunk of body/ Still gets hives in different places long after 2nd booster; Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.; Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.; This spontaneous case was reported by a patient and describes the occurrence of ORAL DISORDER (Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.), CORNEAL LESION (Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.) and URTICARIA (2 weeks after 2nd booster patient had chronic hives, patient had Urticaria/patient had a more aggressive bout of hives/had a major reaction with hives all over trunk of body/ Still gets hives in different places long after 2nd booster) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: J&J Covid-19 vaccine (Primary dose) in April 2021. Past adverse reactions to the above products included No adverse event with J&J Covid-19 vaccine. Concurrent medical conditions included Seasonal allergy (Seasonal allergy in spring) and Grass allergy. Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Seasonal allergy.   In December 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Jun-2022, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In June 2022, the patient experienced ORAL DISORDER (Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.) and CORNEAL LESION (Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.). On 17-Jun-2022, the patient experienced URTICARIA (2 weeks after 2nd booster patient had chronic hives, patient had Urticaria/patient had a more aggressive bout of hives/had a major reaction with hives all over trunk of body/ Still gets hives in different places long after 2nd booster). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Hives, at an unspecified dose and frequency; FAMOTIDINE (PEPCID [FAMOTIDINE]) at a dose of 40 milligram once a day; FAMOTIDINE (PEPCID [FAMOTIDINE]) at a dose of 40 milligram twice a day; PREDNISONE at a dose of 10 milligram once a day; PREDNISONE at a dose of 40 mg for 1 week. and METHYLPREDNISOLONE SODIUM SUCCINATE (SOLUMEDROL) at an unspecified dose and frequency. At the time of the report, ORAL DISORDER (Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.) and CORNEAL LESION (Patient stated that after the 2nd booster, patient also had a couple lesions under the left eye , and bottom lips.) outcome was unknown and URTICARIA (2 weeks after 2nd booster patient had chronic hives, patient had Urticaria/patient had a more aggressive bout of hives/had a major reaction with hives all over trunk of body/ Still gets hives in different places long after 2nd booster) had not resolved.            It was reported that patient had a major reaction with hives all over trunk of body and it went away a month ago. She still gets hives in different places but they were not as intense because patient took medications.  Treatment medication included steroids, Zyrtec 40 mg daily, Zyrtec to 20mg twice a day, and Benadryl in the middle of the night if had reaction after taking Zyrtec, took Benadryl twice this week.   Most recent FOLLOW-UP information incorporated above includes: On 04-Oct-2022: Follow up received contains significant information updated patient demographics, suspect product details, concomitant medication, treatment medication and event.